This statistic depicts small molecules sales at risk due to patent expirations in the U.S. from 2009 to 2022. According to the data, in 2009, 17.8 billion U.S. dollars were at risk due to loss of exclusivity.
Projected sales at risk due to patent expiry 2009-2022
Small molecules sales at risk due to patent expirations in the U.S. from 2009 to 2022
(in billion U.S. dollars)
Basic Account
Get to know the platform
You only have access to basic statistics.
This statistic is not included in your account!
Premium Account
Your perfect start with Statista
- Instant access to 1m statistics
- Download in XLS, PDF & PNG format
- Detailed references
$59 / Month *
Corporate Account
Full access
Corporate solution including all features.
* All products require an annual contract.
Prices do not include sales tax.
Prices do not include sales tax.
Further Content: You might find this interesting as well
Statistics
- Loss of Neupogen sales to U.S. biosimilars 2015-2017
- growth in 90 day prescriptions U.S. 2013-2020
- Loss of Lantus sales to U.S. biosimilars 2015-2017
- Percentage chronic therapy dispensed as 90 day prescriptions 2013-2020
- Generics share of prescription spending in the U.S. by formulation 2012 vs. 2017
- Share of 90 day prescriptions that are mail or retail dispensed 2013-2020
- Generic market share value change worldwide 2006 vs. 2016, by region
- U.S. total vs. generic dispensed prescription numbers 2017, by formulation
- Generic share of dispensed prescriptions by formulation U.S. 2012 vs. 2017
- Spending on dispensed total vs. generic prescriptions in the U.S. 2017
- Generic market share change in unit volume worldwide 2006 vs. 2016, by region
- Number of ANDAs received in U.S. 2009-2017
- Share of top generic purchasing operations in U.S. 2017
- Growing unbranded generic corporations by absolute Rx growth U.S. 2017
- Average number of ANDAs received per month in U.S. 2009-2017
- Italy: average price of drugs provided by the NHS 2010-2018
- Top antipsychotic drugs by prescriptions dispensed in the U.S. 2011-2012
- Monthly value of medicament imports into Finland 2018
- Cardiovascular system pharmaceutical consumption in Slovenia 2006-2016
- Italy: Cetilar market share out of the topical analgesic market value 2015-2017
Further related statistics
Association for Accessible Medicines, & IQVIA. (February 13, 2018). Small molecules sales at risk due to patent expirations in the U.S. from 2009 to 2022 (in billion U.S. dollars) [Graph]. In Statista. Retrieved December 10, 2019, from https://www.statista.com/statistics/869784/projected-sales-at-risk-due-to-loss-of-exclusivity/
Association for Accessible Medicines, und IQVIA. "Small molecules sales at risk due to patent expirations in the U.S. from 2009 to 2022 (in billion U.S. dollars)." Chart. February 13, 2018. Statista. Accessed December 10, 2019. https://www.statista.com/statistics/869784/projected-sales-at-risk-due-to-loss-of-exclusivity/
Association for Accessible Medicines, IQVIA. (2018). Small molecules sales at risk due to patent expirations in the U.S. from 2009 to 2022 (in billion U.S. dollars). Statista. Statista Inc.. Accessed: December 10, 2019. https://www.statista.com/statistics/869784/projected-sales-at-risk-due-to-loss-of-exclusivity/
Association for Accessible Medicines, and IQVIA. "Small Molecules Sales at Risk Due to Patent Expirations in The U.S. from 2009 to 2022 (in Billion U.S. Dollars)." Statista, Statista Inc., 13 Feb 2018, https://www.statista.com/statistics/869784/projected-sales-at-risk-due-to-loss-of-exclusivity/
Association for Accessible Medicines & IQVIA, Small molecules sales at risk due to patent expirations in the U.S. from 2009 to 2022 (in billion U.S. dollars) Statista, https://www.statista.com/statistics/869784/projected-sales-at-risk-due-to-loss-of-exclusivity/ (last visited December 10, 2019)